BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 24172042)

  • 21. Targeting EGFR of triple-negative breast cancer enhances the therapeutic efficacy of paclitaxel- and cetuximab-conjugated nanodiamond nanocomposite.
    Liao WS; Ho Y; Lin YW; Naveen Raj E; Liu KK; Chen C; Zhou XZ; Lu KP; Chao JI
    Acta Biomater; 2019 Mar; 86():395-405. PubMed ID: 30660004
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EGFR signaling in breast cancer: bad to the bone.
    Foley J; Nickerson NK; Nam S; Allen KT; Gilmore JL; Nephew KP; Riese DJ
    Semin Cell Dev Biol; 2010 Dec; 21(9):951-60. PubMed ID: 20813200
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the EGFR/PCNA signaling suppresses tumor growth of triple-negative breast cancer cells with cell-penetrating PCNA peptides.
    Yu YL; Chou RH; Liang JH; Chang WJ; Su KJ; Tseng YJ; Huang WC; Wang SC; Hung MC
    PLoS One; 2013; 8(4):e61362. PubMed ID: 23593472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Met interacts with EGFR and Ron in canine osteosarcoma.
    McCleese JK; Bear MD; Kulp SK; Mazcko C; Khanna C; London CA
    Vet Comp Oncol; 2013 Jun; 11(2):124-39. PubMed ID: 22235915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
    Kommoss F; Colley M; Hart CE; Franklin WA
    Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MUC4 overexpression augments cell migration and metastasis through EGFR family proteins in triple negative breast cancer cells.
    Mukhopadhyay P; Lakshmanan I; Ponnusamy MP; Chakraborty S; Jain M; Pai P; Smith LM; Lele SM; Batra SK
    PLoS One; 2013; 8(2):e54455. PubMed ID: 23408941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PUMA and BIM are required for oncogene inactivation-induced apoptosis.
    Bean GR; Ganesan YT; Dong Y; Takeda S; Liu H; Chan PM; Huang Y; Chodosh LA; Zambetti GP; Hsieh JJ; Cheng EH
    Sci Signal; 2013 Mar; 6(268):ra20. PubMed ID: 23532334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
    Martin JL; de Silva HC; Lin MZ; Scott CD; Baxter RC
    Mol Cancer Ther; 2014 Feb; 13(2):316-28. PubMed ID: 24337110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sensory epithelium of the vomeronasal organ express TrkA-like and epidermal growth factor receptor in adulthood. An immunohistochemical study in the horse.
    Garcia-Suarez O; Germanà G; Naves FJ; Ciriaco E; Represa J; Vega JA
    Anat Rec; 1997 Mar; 247(3):299-306. PubMed ID: 9066907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone-induced phosphorylation of epidermal growth factor (EGF) receptor in 3T3-F442A cells. Modulation of EGF-induced trafficking and signaling.
    Huang Y; Kim SO; Jiang J; Frank SJ
    J Biol Chem; 2003 May; 278(21):18902-13. PubMed ID: 12642595
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
    Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
    Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
    Mueller KL; Hunter LA; Ethier SP; Boerner JL
    Cancer Res; 2008 May; 68(9):3314-22. PubMed ID: 18451158
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein tyrosine kinase Syk modulates EGFR signalling in human mammary epithelial cells.
    Ruschel A; Ullrich A
    Cell Signal; 2004 Nov; 16(11):1249-61. PubMed ID: 15337524
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability.
    Powell CA; Nasser MW; Zhao H; Wochna JC; Zhang X; Shapiro C; Shilo K; Ganju RK
    Oncotarget; 2015 Mar; 6(8):6373-85. PubMed ID: 25779666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The erbB-2 mitogenic signaling pathway: tyrosine phosphorylation of phospholipase C-gamma and GTPase-activating protein does not correlate with erbB-2 mitogenic potency.
    Fazioli F; Kim UH; Rhee SG; Molloy CJ; Segatto O; Di Fiore PP
    Mol Cell Biol; 1991 Apr; 11(4):2040-8. PubMed ID: 1672440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
    El Guerrab A; Zegrour R; Nemlin CC; Vigier F; Cayre A; Penault-Llorca F; Rossignol F; Bignon YJ
    PLoS One; 2011; 6(9):e25080. PubMed ID: 21966417
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
    Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
    Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WBP2 Downregulation Inhibits Proliferation by Blocking YAP Transcription and the EGFR/PI3K/Akt Signaling Pathway in Triple Negative Breast Cancer.
    Song H; Wu T; Xie D; Li D; Hua K; Hu J; Fang L
    Cell Physiol Biochem; 2018; 48(5):1968-1982. PubMed ID: 30092563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
    Jin Q; Esteva FJ
    J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):485-98. PubMed ID: 19034632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor potentiates EGFR(Y992/1173)-mediated therapeutic response of triple negative breast cancer cells to cold atmospheric plasma-activated medium.
    Wang P; Zhou R; Zhou R; Feng S; Zhao L; Li W; Lin J; Rajapakse A; Lee CH; Furnari FB; Burgess AW; Gunter JH; Liu G; Ostrikov KK; Richard DJ; Simpson F; Dai X; Thompson EW
    Redox Biol; 2024 Feb; 69():102976. PubMed ID: 38052106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.